Drug Profile


Alternative Names: ACU-NCT-001; ATV-02; N-chlorotaurine - Manhattan Pharmaceuticals; NCT - Pathogenics

Latest Information Update: 21 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Innsbruck
  • Developer Medical University of Vienna; OPKO Health; Pathogenics
  • Class Alkanesulfonic-acids; Antibacterials; Antifungals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acanthamoeba infections; Infectious conjunctivitis; Otitis externa; Sinusitis; Skin ulcer

Most Recent Events

  • 25 Feb 2008 Antimicrobial data from a preclinical trial in acanthamoeba infections released by OPKO Health and Pathogenics Inc.
  • 12 Jul 2007 Opko Corporation is now called Opko Health
  • 27 Mar 2007 eXegenics has merged with Acuity Pharmaceuticals to form Opko Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top